Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company is focusing on ongoing capex projects like doubling CPVC and ECH capacities and wind-solar hybrid power plant using internal resources. They have also acquired land for future expansion and are evaluating new projects, but details or plans about raising capital through debt or equity have not been disclosed. Interest cost discussion indicates existing debt management but no mention of new borrowing. Overall, there is no explicit indication of fresh fundraising activities in the current or nea

Any current/future capex/capital investment/strategic investment?

Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants. A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity. Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27. Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site. They have acquired ~100 acres near the existing complex at Dahej for

Future growth expectations in sales/revenue/volumes?

Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28. The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26. Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28. New product evaluations and project

Future growth expectations in earnings/operating earnings/profits/EPS?

Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries. The derivatives and specialty business revenue contribution aims to increase from 50% in Q1 FY'26 to 70% by FY'28. Capex projects including doubling capacity of CPVC resin, Epichlorohydrin (ECH) plant, and a 19.8 MW wind-solar hybrid power plant are on schedule, expected to positively impact earnings. The newly commissioned Chlorotoluene value chain is anticipated to generate sizable revenue by end FY'26, contributing to growth in FY'27 and FY'28. Improvement in

Current/ Expected Orderbook/ Pending Orders?

Chlorotoluene plant is currently in trial stage, with commercial orders expected to start from Q4 FY '26; exact revenue from this is not yet specified but clarity expected by Q4. Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market. No specific details provided about a disclosed orderbook or pending orders for other products in this transcript. Trial orders for Chlorotoluenes are ongoing, commercial scale ramp-up anticipated by end of Q3 FY '26. The company ex

IN US

Sale is live|00:00:00left today

Epigral LtdQ2 FY25Chemicals & Petrochemicals

Epigral Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,106P/E: 15.8Market Cap: ₹5.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries.
→Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28.
→The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26.
→Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28.
→New product evaluations and projects on existing and newly acquired land at Dahej aim to add growth beyond 2028, focusing on import substitution chemicals with expected double-digit CAGR (~12-13%) over 10 years.
→Demand slowdown due to monsoon is temporary; demand expected to pick up from Q3 FY26 onwards.
→Overall growth is underpinned by operational efficiency and strategic infrastructure investments.

Margin guidance

Category 3

→Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.
→The derivatives and specialty business revenue contribution aims to increase from 50% in Q1 FY'26 to 70% by FY'28.
→Capex projects including doubling capacity of CPVC resin, Epichlorohydrin (ECH) plant, and a 19.8 MW wind-solar hybrid power plant are on schedule, expected to positively impact earnings.
→The newly commissioned Chlorotoluene value chain is anticipated to generate sizable revenue by end FY'26, contributing to growth in FY'27 and FY'28.
→Improvement in operational efficiencies and optimized plant utilization (post maintenance) expected from Q3 FY'26 supports margin stability and profit growth.
→Shift to new tax regime with a lower tax rate (25.17%) improves profit after tax and EPS going forward.
→Expansion projects on existing and new land parcels evaluated to sustain double-digit CAGR growth beyond 2028 with good ROCE.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The transcript does not mention any current or planned fundraising through debt or equity.
→The company is focusing on ongoing capex projects like doubling CPVC and ECH capacities and wind-solar hybrid power plant using internal resources.
→They have also acquired land for future expansion and are evaluating new projects, but details or plans about raising capital through debt or equity have not been disclosed.
→Interest cost discussion indicates existing debt management but no mention of new borrowing.
→Overall, there is no explicit indication of fresh fundraising activities in the current or near future based on the transcript.

Order book

→Chlorotoluene plant is currently in trial stage, with commercial orders expected to start from Q4 FY '26; exact revenue from this is not yet specified but clarity expected by Q4.
→Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market.
→No specific details provided about a disclosed orderbook or pending orders for other products in this transcript.
→Trial orders for Chlorotoluenes are ongoing, commercial scale ramp-up anticipated by end of Q3 FY '26.
→The company expects consistent growth in its multiproduct pipeline aligned with expansion and diversification strategies.

Capex plans

Yes

→Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
→A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity.
→Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27.
→Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site.
→They have acquired ~100 acres near the existing complex at Dahej for 7 years of growth, where they plan to develop new chemistry aligned with import substitution to drive double-digit growth and good ROCE.
→Details of this new expansion are being finalized and will be announced once approved by the Board, likely in the next couple of quarters.

How does Epigral Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Epigral Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Epigral Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio